A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules

Exclusion Criteria

• •A previous anaphylactic reaction to any vaccine or vaccine-related component.
• •Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
• •A known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as participants with congenital or acquired defects in B-cell function, those receiving chronic systemic (oral, intravenous, or intramuscular) corticosteroid therapy, or those receiving immunosuppressive therapy.
• •History of microbiologically proven disease caused by Neisseria meningitidis or Neisseria gonorrhoeae.
• •Significant neurological disorder or history of seizure (excluding simple febrile seizure).
• •Any neuroinflammatory or autoimmune condition, including, but no limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
• •Participants receiving any allergen immunotherapy with a nonlicensed product or receiving allergen immunotherapy with a licensed product and are not on stable maintenance doses.
• •Receipt of any blood products, including immunoglobulin, within 6 months before the first study vaccination.
• •Current use of systemic antibiotics with no foreseeable date of discontinuation prior to anticipated date of enrollment (first vaccination).